Recently, a case of ICI-induced polymyalgia rheumatica controlled by the MEK inhibitor cobimetinib showed the in vivo anti-inflammatory potential of targeting the MAPK signaling pathway [39]. Here, MAP2K7 is linked to polymyalgia rheumatica.